The UK NICE has issued a negative draft guidance on Nusinersen. NICE motivates its current position mainly on the grounds of the high acquisition cost of Nusinersen and the uncertainty on long term effect. This is not a final decision and a second NICE Appraisal Committee meeting is expected for October 2018. NICE’s language makes think that a further confidential price discount may change the guidance to positive. The NICE press release can be read clicking the link below:
NICE negative draft guidance on Nusinersen
Could a more coordinated EU HTA improve access to new healthcare technologies, favour development of EU-wide evidence development infrastructure and reduce fragmentation? These and other related topics will be discussed on July 9th in Brussels in a meeting organised by the EU Commission and that will involve relevant stakeholders. Here below a link to the meeting webpage:
Today the German G-BA published their decision on added benefit of Tesaro’s orphan drug Zejula (niraparib) for ovarian cancer. The G-BA assigned a ‘non-quantifiable benefit’ to Zejula.
June 1st 2018 – The German G-BA has started the procedure for the benefit assessment of Takeda (Tigenix) Alofisel®️ (darvadstrocel). The publication of the benefit assessment is expected on September 3rd and a final resolution end of November 2018.
link to G-BA webpage
We need to think at new ways to fund general population screening programs
link to article